January 7, 2021: Pall Corporation expands production capacity in the United States and Europe to support industry demand

April 1, 2021: Major capacity expansion underway to support increase in industry demand

Flexible, scalable solutions to support process development and clinical monoclonal antibody production and monoclonal antibody manufacturing.